Meeting
2020 ASCO Virtual Scientific Program
A phase Ib/II study of niraparib plus temozolomide plus atezolizumab versus atezolizumab as maintenance therapy in extensive-stage small cell lung cancer (TRIO-US L-06).
Authors
Amy Lauren Cummings
David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA
Amy Lauren Cummings , David Dae-Young Kim , Lee S. Rosen , Edward B. Garon , Zev A. Wainberg , Dennis J. Slamon , Jonathan Wade Goldman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Small Cell Lung Cancer
Clinical Trial Registration Number
NCT03830918
Citation
J Clin Oncol 38: 2020 (suppl; abstr TPS9084)
DOI
10.1200/JCO.2020.38.15_suppl.TPS9084
Abstract #
TPS9084
Poster Bd #
277
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Long-term effectiveness and treatment sequences in patients with extensive stage small cell lung cancer receiving atezolizumab plus chemotherapy: Results of the IFCT-1905 CLINATEZO real-world study.
First Author: Lionel Falchero
Poster
2023 ASCO Annual Meeting
Phase 2 multicenter trial of rucaparib and nivolumab as maintenance therapy following first-line platinum-based chemotherapy in patients with advanced biliary tract cancer (BTC): BilT-02.
First Author: Vaibhav Sahai
Poster
2023 ASCO Annual Meeting
Phase II study of durvalumab plus olaparib as maintenance therapy in extensive-stage small-cell lung cancer (TRIDENT): Preliminary efficacy and safety results.
First Author: Yan Huang
